LLY · 10-Q · 2026Q2 · Full report
Business Development / Acquisitions
ELI LILLY & Co · 2026-08-05 · Importance 65 · Surprise 60 · In source text
Lilly paid $13.3 billion during the first six months of 2026 for business development activity, primarily involving Centessa, Kelonia, Orna, Ventyx, and Ajax. In July 2026, Lilly paid approximately $2.0 billion to acquire companies supporting an infectious disease portfolio. Lilly also entered into an agreement to acquire AtaiBeckley Inc., with approximately $2.8 billion potentially payable at closing subject to conditions. The acquisition activity was funded partly with proceeds from a $9.0 billion May 2026 long-term debt offering.
Key facts
- Paid $13.3 billion in 2026 related to business development activity, primarily driven by acquisitions of Centessa, Kelonia, Orna, Ventyx, and Ajax. source
- The company has entered into an agreement to acquire AtaiBeckley Inc., subject to closing conditions, with a potential amount payable at closing of approximately $2.8 billion. source
- In July 2026, the company paid approximately $2.0 billion to acquire companies to build an infectious disease portfolio. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | -9.3% | Paid $13.3 billion in 2026 related to business development activity, primarily driven by acquisitions of Centessa, Kelonia, Orna, Ventyx,… |
| cash | negative | probable | -1.0% | The company has entered into an agreement to acquire AtaiBeckley Inc., subject to closing conditions, with a potential amount payable at… |